Table 1

The basic demographic and disease characteristics
TACE + Sorafenib TACE P
(n = 45) (n = 45)
Age 51 ± 11.7 49 ± 11.0 >0.05
Men/women 41/4 41/4 >0.05
PVT 20 23 >0.05
Distant metastasis 11 12 >0.05
Prior surgery 19 14 >0.05
ECOG >0.05
0 43 41
1 2 4
Child pugh >0.05
A 33 35
B 12 10
C 0 0
AFP >0.05
<400 ng/ml 16 19
≥400 ng/ml 29 26
Diagnosis of Hepatitis >0.05
HBV 38 37
HCV 0 0
None 7 8
Tumor size, n (%)
>5 cm
35(77.78) 36(80.00)
≤5 cm
10(22.22) 9(20.00)
Tumor type, n (%) >0.05
Massive
13(28.89) 10(22.22)
Multifocal
16(35.56) 18(40.00)
Diffuse
16(35.56) 17(37.78)
BCLC stage >0.05
A 0 0
B 16 17
C 29 28

TACE: transcatheter arterial chemoembolization; TACE-S: TACE combined with sorafenib; BCLC: Barcelona Clinic Liver Cancer; ECOG PS: Eastern Cooperative Oncology Group Performance Status; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein, AST, aspartate aminotransferase.

Qu et al.

Qu et al. BMC Cancer 2012 12:263   doi:10.1186/1471-2407-12-263

Open Data